Authors
Spellman is a urology resident at Duke University Medical Center, Durham, North Carolina.
Martin is a urologist with Central Ohio Urology Group in Gahanna.
Yasin is a genitourinary oncology fellow at Vanderbilt University Medical Center, Nashville, Tennessee.
Almassi is a urologist at Glickman Urological & Kidney Institute at the Cleveland Clinic in Ohio.
Haywood is an associate staff urologist at Cleveland Clinic Glickman Urological and Kidney Institute in Cleveland, Ohio.
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
New agents, biomarkers shape recent advances in bladder cancer
5

